For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Hepatoblastoma Treatment Study
A risk-based treatment approach will maintain or improve event-free survival (EFS), decrease acute and long-term chemotherapy toxicity, and identify new agents in the treatment of children with hepatoblastoma.
In order to participate you must meet the following criteria:
- Are less than 21 years of age at the time of diagnosis.
- Have been newly diagnosed with histologically-proven hepatoblastoma.
This is a partial list of elgibility requirements.